1. Home
  2. MRSN

MRSN

Mersana Therapeutics Inc.

Logo Mersana Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Founded: N/A Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 449.4M IPO Year: 2017
Target Price: $5.57 AVG Volume (30 days): 2.2M
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.48 EPS Growth: N/A
52 Week Low/High: $0.80 - $9.62 Next Earning Date: 05-07-2024
Revenue: $36,855,000 Revenue Growth: 38.65%
Revenue Growth (this year): 8.09% Revenue Growth (next year): -18.16%

Share on Social Networks: